Wells Fargo analyst Peter Costa upgraded Molina Healthcare (NYSE: MOH) from Market Perform to Outperform.
Friday, May 31, 2019
Thursday, May 30, 2019
BeiGene: China OKs application to import Abraxane for pancreatic cancer
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the China National Medical Products Administration (NMPA, formerly known as CFDA) has accepted the supplemental import drug application for ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), in combination with gemcitabine, as a first-line treatment of patients with metastatic adenocarcinoma of the pancreas (mPC). ABRAXANE was first approved in China in 2008 for the treatment of patients with metastatic breast cancer. It is currently marketed in China by BeiGene under an exclusive license from Celgene Corporation.
BeiGene: China accepts application for new urothelial carcinoma med
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the China National Medical Products Administration (NMPA, formerly known as CFDA) has accepted a supplemental new drug application (sNDA) for tislelizumab, an investigational anti-PD-1 antibody, for the treatment of patients with previously treated locally advanced or metastatic urothelial carcinoma (UC).
“The development program for tislelizumab is achieving its milestones swiftly with our first solid-tumor filing for patients with previously treated urothelial carcinoma following our initial filing last year for patients with relapsed/refractory classical Hodgkin’s lymphoma. We sincerely hope that this submission, if approved, can bring a meaningful treatment option for patients with UC in China,” said Dr. Xiaobin Wu, General Manager of China and President of BeiGene. “We believe that the broad development program for this anti-PD1 inhibitor, along with manufacturing capabilities that are nearing completion, and non-clinical data presented earlier this year, reinforce tislelizumab as a potentially differentiated immuno-oncology compound. We are excited by its prospects to improve the way people with cancer are treated around the world.”
The sNDA is supported by a clinical, non-clinical, and CMC data package, including the results from a pivotal Phase 2 study of tislelizumab in 113 Chinese and South Korean patients with previously treated PD-L1+ locally advanced or metastatic urothelial carcinoma (chinadrugtrials.org registration number: CTR20170071). A recent independent review of data showed that, with a median follow-up time of 8 months at the data cutoff, overall response rate (ORR) in 104 efficacy-evaluable patients was 23.1 percent, including eight (7.7 percent) confirmed complete responses (CRs) and 16 (15.4 percent) confirmed partial responses (PRs). Frequency and severity of adverse events were generally consistent with the previously reported Phase 1/2 safety and tolerability data for tislelizumab, or, in the case of certain immune-related adverse events, consistent with previous reports of other PD-1 antibodies. Full results of the study are planned to be presented at an upcoming medical conference.
Powerful new cancer drugs can trigger diabetes — and no one is certain why
The first two rounds of treatment went off without a hitch. But last November, after receiving a third dose of potent immunotherapy for his skin cancer, Rich Lenihan started to feel tired and weak.
He was urinating constantly, and no amount of water could abate his thirst. A blood test revealed glucose levels that were through the roof.
Lenihan, at age 62, had developed a disease akin to type 1 diabetes — formerly called “juvenile” diabetes — a rare complication of drugs known as checkpoint inhibitors that rev up the body’s immune assault on tumor tissue.
“The good news is we know what’s wrong with you,” Lenihan recalled his doctors telling him — as they whisked him off to the ICU.
The bad news: He would need to control his glucose with insulin shots for the rest of his life.
Roughly 1% of patients receiving immunotherapy drugs experience the same irreversible side effect. Making matters worse, oncologists have little clue why.
“There are a lot of case reports,” said Dr. Kevan Herold, a clinical immunologist at the Yale School of Medicine who last year published a case series of his own. “But there isn’t a good understanding yet of who’s most likely to develop these adverse events from checkpoint inhibitors.”
On Wednesday, the Parker Institute for Cancer Immunotherapy, JDRF (formerly called the Juvenile Diabetes Research Foundation), and the Helmsley Charitable Trust announced they are joining forces to launch a $10 million, three-year research initiative designed to identify the root causes of drug-induced diabetes among cancer patients.
Eventually, researchers involved in the project hope to discover new therapeutic strategies for preventing diabetic complications without sacrificing any of the cancer-destroying potential of livesaving immunotherapy drugs.
“But the first step,” said Dr. Zoe Quandt, an endocrinologist at the University of California, San Francisco, “is understanding the immune responses of patients so we can consider which drugs would be good ones to try.”
‘A lot to handle’
Autoimmune-related toxicity problems have dogged checkpoint inhibitors since their earliest days of clinical testing — although generally patients see them as a small price to pay for a treatment that can beat metastatic cancer back into remission.
Participants in some of the first trials for Yervoy, a drug that blocks an immune-cell brake called CTLA-4, developed inflammatory diseases of the pituitary gland, thyroid, and other organs. More cases soon followed among patients given the next generation of agents, drugs such as Opdivo and Keytruda that target PD-1, another brake pedal found on T cells.
Those complications, if caught quickly, rarely prove debilitating for all that long; once- or twice-daily hormone replacement therapy can usually make up for the lost organ function.
Insulin-dependent diabetes is a different story. It’s more of a daily slog, with patients having to carefully and constantly track their blood sugar levels and self-inject different types of insulin at different times of the day — or else risk falling into a diabetic coma or having one’s blood turn into a toxic, acidic stew.
“Type 1 diabetes is like being in hell, man. It’s horrible,” said Jaime Vidal, 79, a retired mailman from San Bruno, Calif., who developed the disease two months ago after receiving Opdivo through a trial protocol for people with operable cancer of the esophagus. “If I knew then, when I opted for the clinical trial, what type 1 diabetes entailed, I would never have gone for the immunotherapy. Never. I would have taken the chance of the cancer coming back.”
The condition can also come on quickly. Blood sugar levels spike precipitously. Many patients land in intensive care. Once discharged, they face a particularly hard-to-control form of the disease, known as “brittle” diabetes, in which glucose levels can quickly swing from too high to too low, or vice versa. Even the smallest insulin injection can throw the balance out of whack.
“It can be a lot to handle,” said Dr. Monica Girotra, an endocrinologist at Memorial Sloan Kettering Cancer Center.
The only potential upside: A self-directed attack on beta cells may be a sign of amped-up immunity more generally. And according to case reports, patients who develop drug-induced diabetes tend to have stronger and more long-lasting anti-cancer responses to checkpoint inhibitor treatments. “So that’s kind of the silver lining,” Quandt said.
The new grant money will go toward launching a massive prospective study involving 1,500 to 2,000 patients undergoing checkpoint inhibitor therapy at more than 30 community hospitals and clinics across the United States. Only a few dozen may eventually develop diabetes — but researchers won’t know whom in advance. So to catch that fulminant disease process in action, they plan to collect blood samples from every patient along each step of their therapeutic odysseys.
For those ultimately diagnosed with diabetes (and some who aren’t), scientists will then throw the kitchen sink of single-cell “omics” technologies on their samples before, during, and after disease onset, in an exploratory effort to uncover biomarkers underpinning the phenomenon.
“I’m pretty open-minded about what mechanistically can be happening,” Parker Institute president and CEO Jeff Bluestone told STAT. “And I’m really optimistic that we’re going to learn a lot quickly.”
Later this year, the National Cancer Institute will also start building a repository of tissue and blood specimens collected from patients who experience immune-related side effects after undergoing checkpoint inhibitor therapy. “We’ll then backtrack to learn more about what might have happened along the way,” said NCI senior investigator Dr. Elad Sharon.
But whereas Bluestone and his colleagues — including Herold and other physician-scientists from Yale, UCSF, the Benaroya Research Institute in Seattle, and the Dana-Farber Cancer Institute in Boston — plan to prospectively stockpile biospecimens from a single registry of patients treated as part of routine clinical care, the NCI team will work after the fact to centralize samples amassed through dozens of government-backed immunotherapy trials. “It’s really a complementary effort,” Sharon said.
Dr. Juan Jaume, an endocrinologist at the University of Toledo Medical Center, welcomes both initiatives. “We should not withhold the treatment of cancer just because of this side effect,” he said, “but we need to learn more about it so we can provide safeguards.”
Two of a kind
The research could also have spillover benefits beyond the cancer clinic.
There are already hints of a genetic predisposition shared by people with the two forms of insulin-dependent diabetes. And now by studying cancer patients whose bodies begin destroying insulin-producing cells in the pancreas after drug treatment, scientists hope to discover why this same process occurs spontaneously in children and young adults with type 1 diabetes.
“If the lessons that we learn from this study are generalizable,” said Ben Williams, a program officer for the Helmsley Trust’s T1D program, “then this could help a lot of people with the spontaneous diabetes that an otherwise healthy kid might get.”
For his part, Lenihan, a software quality assurance engineer from Griswold, Conn., who blogs about his struggle with melanoma, is getting used to living without a working pancreas — monitoring blood sugar levels with the device he wears on his abdomen, and pricking himself with insulin several times each day.
His latest scans this month came back clean, with no signs of active disease growth in his skin, lungs, brain, or anywhere else where metastatic lesions had cropped up before. But he had to stop taking immunotherapy after developing colitis, another autoimmune-related side effect, and now the prospect of the cancer returning weighs heavily on his mind.
His doctor, Yale oncologist Dr. Mario Sznol, is less concerned, though.
“He’s got a pretty good chance of remaining in remission for a very long time, maybe forever,” Sznol said.
As for living with diabetes? “That’s the unfortunate trade-off.”
Genmab gets FDA priority review for myeloma combo
- U.S. FDA grants Priority Review for daratumumab in combination with bortezomib, thalidomide and dexamethasone as treatment for newly diagnosed patients with multiple myeloma who are candidates for autologous stem cell transplant
- September 26, 2019 PDUFA date
Zynerba to Present at FDA CBD Hearing
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Ray Mannion, Zynerba’s Vice President of Manufacturing, will provide a formal presentation during the U.S. Food and Drug Administration’s (FDA) Public Hearing on Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds. As noted in the Federal Register, the public hearing is scheduled from 8:00 a.m. to 6:00 p.m. ET tomorrow, May 31, 2019.
Slides from Mr. Mannion’s presentation, entitled ‘Cannabinoid Manufacturing and Product Quality’, are now available on Zynerba’s corporate website at https://zynerba.com/publications/.
Subscribe to:
Posts (Atom)